China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its mRNA vaccine SYS6017. The trial will focus on herpes zoster, a painful condition caused by the reactivation of the varicella zoster virus (VZV).
Vaccine Composition and Development
SYS6017 is composed of mRNA molecules encoding VZV glycoprotein E (gE protein) encapsulated in lipid nanoparticles. The vaccine is under development for the prevention of herpes zoster infection. Preclinical studies have demonstrated that SYS6017 can effectively induce both humoral and cellular immune responses, indicating a robust immune response against the virus. Additionally, the vaccine has shown a favorable safety profile in preclinical studies, suggesting fewer adverse reactions in clinical trials.
Future Outlook
With the NMPA’s approval, CSPC Pharmaceutical is poised to advance the clinical development of SYS6017. The upcoming clinical trial will provide valuable data on the vaccine’s safety and efficacy in preventing herpes zoster, potentially offering a new preventive option for individuals at risk of this condition.-Fineline Info & Tech
